$CDXS
CODEXIS, INC. Stock $cdxs

$cdxs Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-K Financial Statement

#000120037515000008 Filed on March 06, 2015

Income Statement

Concept	2015 Q1	2014 Q4	2014
Revenue	$6.798M	$14.19M	$35.31M
YoY Change	-3.9%	48.98%	10.6%
Cost Of Revenue	$1.456M	$3.550M	$9.726M
YoY Change	-42.31%	-25.48%	-33.17%
Gross Profit	$5.342M	$10.64M	$25.58M
YoY Change	17.41%	123.48%	47.29%
Gross Profit Margin	78.58%	74.98%	72.45%
Selling, General & Admin	$5.578M	$5.150M	$21.94M
YoY Change	-8.74%	-10.95%	-18.47%
% of Gross Profit	104.42%	48.4%	85.76%
Research & Development	$5.293M	$5.050M	$22.76M
YoY Change	9.5%	-42.8%	-28.0%
% of Gross Profit	99.08%	47.46%	88.95%
Depreciation & Amortization	$558.0K	$1.470M	$6.680M
YoY Change	-45.08%	-40.49%	-35.21%
% of Gross Profit	10.45%	13.82%	26.11%
Operating Expenses	$12.33M	$10.19M	$54.42M
YoY Change	-8.49%	-47.41%	-25.52%
Operating Profit	-$5.529M	$450.0K	-$19.11M
YoY Change	-13.56%	-103.08%	-53.55%
Interest Expense	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
% of Operating Profit		0.0%
Other Income/Expense, Net	$25.00K	-$50.00K	$234.0K
YoY Change	-78.81%	150.0%	-23.03%
Pretax Income	-$5.550M	$400.0K	-$20.98M
YoY Change	-14.68%	-104.06%	-49.68%
Income Tax	$12.00K	$60.00K	-$256.0K
% Of Pretax Income		15.0%
Net Earnings	-$5.562M	$350.0K	-$19.07M
YoY Change	-12.75%	-103.57%	-53.83%
Net Earnings / Revenue	-81.82%	2.47%	-54.01%
Basic Earnings Per Share
Diluted Earnings Per Share	-$143.4K	$9.056K	-$500.0K
COMMON SHARES
Basic Shares Outstanding	39.70M shares	39.55M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q4	2014
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.20M	$26.49M	$26.50M
YoY Change	-8.13%	5.38%	5.58%
Cash & Equivalents	$22.16M	$26.49M	$26.50M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$1.300M	$1.300M	$1.300M
YoY Change	-58.06%	-65.79%	-65.79%
Inventory	$992.0K	$1.395M	$1.400M
Prepaid Expenses
Receivables	$3.215M	$3.870M	$3.900M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.63M	$33.01M	$33.00M
YoY Change	-19.3%	-7.75%	-7.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.499M	$3.995M	$4.000M
YoY Change	-52.69%	-52.7%	-52.38%
Goodwill	$3.241M	$3.241M
YoY Change	0.0%	0.0%
Intangibles	$5.342M	$6.186M
YoY Change	-38.71%	-35.29%
Long-Term Investments	$700.0K	$700.0K	$700.0K
YoY Change	-50.0%	-12.5%	-12.5%
Other Assets	$284.0K	$294.0K	$1.000M
YoY Change	36.54%	-3.92%	0.0%
Total Long-Term Assets	$13.79M	$15.12M	$15.10M
YoY Change	-36.51%	-34.45%	-34.35%
TOTAL ASSETS
Total Short-Term Assets	$27.63M	$33.01M	$33.00M
Total Long-Term Assets	$13.79M	$15.12M	$15.10M
Total Assets	$41.42M	$48.12M	$48.10M
YoY Change	-25.98%	-18.22%	-18.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.952M	$4.673M	$4.700M
YoY Change	-44.02%	17.98%	17.5%
Accrued Expenses	$2.065M	$2.619M	$5.600M
YoY Change	-23.49%	62.47%	7.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.87M	$13.74M	$13.70M
YoY Change	-9.32%	22.64%	22.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.154M	$2.528M	$8.100M
YoY Change	-15.22%	-49.88%	30.65%
Total Long-Term Liabilities	$4.154M	$2.528M	$8.100M
YoY Change	-15.22%	-49.88%	30.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.87M	$13.74M	$13.70M
Total Long-Term Liabilities	$4.154M	$2.528M	$8.100M
Total Liabilities	$16.02M	$16.26M	$21.80M
YoY Change	-17.35%	-6.3%	25.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$281.5M	-$275.9M
YoY Change	6.94%	7.42%
Common Stock	$4.000K	$4.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.62M	$26.31M	$26.30M
YoY Change
Total Liabilities & Shareholders Equity	$41.42M	$48.12M	$48.10M
YoY Change	-25.98%	-18.22%	-18.2%

Cashflow Statement

Concept	2015 Q1	2014 Q4	2014
OPERATING ACTIVITIES
Net Income	-$5.562M	$350.0K	-$19.07M
YoY Change	-12.75%	-103.57%	-53.83%
Depreciation, Depletion And Amortization	$558.0K	$1.470M	$6.680M
YoY Change	-45.08%	-40.49%	-35.21%
Cash From Operating Activities	-$3.848M	$4.970M	$321.0K
YoY Change	60.0%	-227.11%	-101.4%
INVESTING ACTIVITIES
Capital Expenditures	$52.00K	-$30.00K	$302.0K
YoY Change	147.62%	-95.89%	-74.3%
Acquisitions
YoY Change
Other Investing Activities	$10.00K	$0.00	$4.950M
YoY Change	-99.72%	-100.0%	-65.74%
Cash From Investing Activities	-$47.00K	-$30.00K	$4.647M
YoY Change	-101.3%	-93.18%	-64.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$9.000K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$433.0K	30.00K	-$611.0K
YoY Change	157.74%	-106.82%	315.65%
NET CHANGE
Cash From Operating Activities	-$3.848M	4.970M	$321.0K
Cash From Investing Activities	-$47.00K	-30.00K	$4.647M
Cash From Financing Activities	-$433.0K	30.00K	-$611.0K
Net Change In Cash	-$4.328M	4.970M	$4.357M
YoY Change	-518.97%	-203.76%	-144.13%
FREE CASH FLOW
Cash From Operating Activities	-$3.848M	$4.970M	$321.0K
Capital Expenditures	$52.00K	-$30.00K	$302.0K
Free Cash Flow	-$3.900M	$5.000M	$19.00K
YoY Change	60.76%	-257.23%	-100.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	cdxs	Adjustments To Additional Paid In Capital Non Employee Share Based Compensation AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation	12000	USD
CY2012	cdxs	Classof Warrantor Right Exercisesin Period ClassofWarrantorRightExercisesinPeriod	6066	shares
CY2013	cdxs	Classof Warrantor Right Exercisesin Period ClassofWarrantorRightExercisesinPeriod	0	shares
CY2014	cdxs	Classof Warrantor Right Exercisesin Period ClassofWarrantorRightExercisesinPeriod	0	shares
CY2012	cdxs	Defined Contribution Plan Employer Contribution Amount DefinedContributionPlanEmployerContributionAmount	0	USD
CY2012	cdxs	Adjustments To Additional Paid In Capital Non Employee Share Based Compensation AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation	104000	USD
CY2013	cdxs	Adjustments To Additional Paid In Capital Non Employee Share Based Compensation AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation	23000	USD
CY2013	cdxs	Defined Contribution Plan Employer Contribution Amount DefinedContributionPlanEmployerContributionAmount	500000	USD
CY2014	cdxs	Defined Contribution Plan Employer Contribution Amount DefinedContributionPlanEmployerContributionAmount	400000	USD
CY2014	cdxs	Defined Contribution Plan Minimum Employee Eligibility Age DefinedContributionPlanMinimumEmployeeEligibilityAge	P18Y
CY2012	cdxs	Fair Value Adjustmentof Assets Heldforsale FairValueAdjustmentofAssetsHeldforsale	0	USD
CY2013	cdxs	Fair Value Adjustmentof Assets Heldforsale FairValueAdjustmentofAssetsHeldforsale	0	USD
CY2014	cdxs	Fair Value Adjustmentof Assets Heldforsale FairValueAdjustmentofAssetsHeldforsale	698000	USD
CY2012	cdxs	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	165000	USD
CY2013	cdxs	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	0	USD
CY2014	cdxs	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	0	USD
CY2012	cdxs	Gain Lossfrom Extinguishmentof Asset Retirement Obligation GainLossfromExtinguishmentofAssetRetirementObligation	212000	USD
CY2013	cdxs	Gain Lossfrom Extinguishmentof Asset Retirement Obligation GainLossfromExtinguishmentofAssetRetirementObligation	0	USD
CY2014	cdxs	Gain Lossfrom Extinguishmentof Asset Retirement Obligation GainLossfromExtinguishmentofAssetRetirementObligation	0	USD
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	165000	USD
CY2013	cdxs	Reclassificationfrom Accumulated Other Comprehensive Income Current Period Netof Tax ReclassificationfromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetofTax	0	USD
CY2014	cdxs	Reclassificationfrom Accumulated Other Comprehensive Income Current Period Netof Tax ReclassificationfromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetofTax	0	USD
CY2012	cdxs	Stock Issued During Period Value Cancellation StockIssuedDuringPeriodValueCancellation	65000	USD
CY2013	cdxs	Stock Issued During Period Value Cancellation StockIssuedDuringPeriodValueCancellation	465000	USD
CY2014	cdxs	Stock Issued During Period Value Cancellation StockIssuedDuringPeriodValueCancellation	806000	USD
CY2013	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-42000	USD
CY2012	cdxs	Impairment Of Marketable Securities ImpairmentOfMarketableSecurities	753000	USD
CY2013	cdxs	Impairment Of Marketable Securities ImpairmentOfMarketableSecurities	0	USD
CY2014	cdxs	Impairment Of Marketable Securities ImpairmentOfMarketableSecurities	0	USD
CY2013Q4	cdxs	Number Of Marketable Securities NumberOfMarketableSecurities	0	securities
CY2014Q4	cdxs	Number Of Marketable Securities NumberOfMarketableSecurities	0	securities
CY2012Q3	cdxs	Ownership Percentage Threshold Under Stockholder Rights Plan OwnershipPercentageThresholdUnderStockholderRightsPlan	0.15
CY2012	cdxs	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	10397000	USD
CY2013	cdxs	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0	USD
CY2014	cdxs	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	3000000	USD
CY2012	cdxs	Proceedsfrom Maturityof Marketable Securities ProceedsfromMaturityofMarketableSecurities	29885000	USD
CY2013	cdxs	Proceedsfrom Maturityof Marketable Securities ProceedsfromMaturityofMarketableSecurities	13409000	USD
CY2014	cdxs	Proceedsfrom Maturityof Marketable Securities ProceedsfromMaturityofMarketableSecurities	0	USD
CY2012	cdxs	Reclassificationfrom Accumulated Other Comprehensive Income Current Period Netof Tax ReclassificationfromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetofTax	753000	USD
CY2012Q3	cdxs	Tender Offer Portion Of Common Stock TenderOfferPortionOfCommonStock	0.15
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001200375
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39702102	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q2	dei	Entity Public Float EntityPublicFloat	35600000	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	CODEXIS INC
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3961000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4673000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5413000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3870000	USD
CY2012	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-697000	USD
CY2014	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1612000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2619000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	29461000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31452000	USD
CY2012	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	8908000	USD
CY2013	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	6944000	USD
CY2014	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	3311000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-32000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-142000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	298370000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	302379000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5040000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4366000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4608000	USD
CY2012	us-gaap	Advertising Expense AdvertisingExpense	400000	USD
CY2013	us-gaap	Advertising Expense AdvertisingExpense	500000	USD
CY2014	us-gaap	Advertising Expense AdvertisingExpense	300000	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	17000	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	150000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	460000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	428000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	460000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	428000	USD
CY2012	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2013	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	76000	USD
CY2014	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2012	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2013	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2014	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	43000	USD
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3509000	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3374000	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3374000	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7351000	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6797000	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6268000	shares
CY2013Q4	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1571000	USD
CY2013	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1571000	USD
CY2014Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	300000	USD
CY2012	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	30000	USD
CY2013	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	0	USD
CY2014	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	0	USD
CY2013Q4	us-gaap	Assets Assets	58840000	USD
CY2014Q4	us-gaap	Assets Assets	48122000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	35781000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	33007000	USD
CY2013Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	2179000	USD
CY2014Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	0	USD
CY2013Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	2179000	USD
CY2014Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	19889000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	15290000	USD
CY2013Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	235000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	178000	USD
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-45000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	125000	USD
CY2013Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	19654000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	15165000	USD
CY2013Q4	us-gaap	Cash Cash	6000000	USD
CY2014Q4	us-gaap	Cash Cash	11900000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25762000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32003000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22130000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26487000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6241000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9873000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4357000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38351000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39563000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38351000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39563000	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30586000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41199000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19181000	USD
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	30647000	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	14554000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	9726000	USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-371000	USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	185000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-40000	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-366000	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	USD
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-62000	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-59000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2012	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	154000	USD
CY2013	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	19000	USD
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	110000	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	85000	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-47000	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	110000	USD
CY2013Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	186000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2001000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3497000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1114000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3813000	USD
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-7000	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-7000	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	933000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1198000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2697000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4208000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4639000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	86294000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	91589000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	112000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	148000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-110000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	67507000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	70666000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	159000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	101000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2247000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2295000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4194000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4421000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	3626000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	2701000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3043000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2988000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	86294000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	91513000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	186000	USD
CY2014	us-gaap	Disposal Group Not Discontinued Operation Loss Gain On Write Down DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown	188000	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.84
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.08
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2012	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	0	USD
CY2013	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	0	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19327000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	270000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87000	USD
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3625000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2946000	USD
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3814000	USD
CY2014	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P6Y
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15316000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18690000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3374000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2812000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24876000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24876000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9560000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6186000	USD
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1551000	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-24000	USD
CY2012	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0	USD
CY2013	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0	USD
CY2014	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-87000	USD
CY2014	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	760000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	3241000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	3241000	USD
CY2013	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2014	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2013	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2014	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2013Q4	us-gaap	Impairment Charge On Reclassified Assets ImpairmentChargeOnReclassifiedAssets	1571000	USD
CY2014	us-gaap	Impairment Charge On Reclassified Assets ImpairmentChargeOnReclassifiedAssets	698000	USD
CY2014	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2012	us-gaap	Impairment Of Investments ImpairmentOfInvestments	800000	USD
CY2013	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2014	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1582000	USD
CY2014	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1841000	USD
CY2014Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	1700000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-30587000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-41390000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-256000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9716000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1063000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1948000	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	249000	USD
CY2012	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	195000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17392000	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6042000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1493000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2012	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	7000	USD
CY2013	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-108000	USD
CY2014	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	447000	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10399000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-14073000	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6571000	USD
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	204000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-1272000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-364000	USD
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	312000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	117000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2000	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	57000	USD
CY2012	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	126000	USD
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	103000	USD
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	15000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6710000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	308000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	713000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11372000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1629000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1587000	USD
CY2012	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	0	USD
CY2013	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	2179000	USD
CY2014	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	-333000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1789000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1629000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4195000	USD
CY2012	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3290000	USD
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	130000	USD
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-530000	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3186000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	185000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-92000	USD
CY2012	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	197000	USD
CY2013	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2724000	USD
CY2014	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	555000	USD
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1330000	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-337000	USD
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	78000	USD
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1857000	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3051000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-850000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	339000	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-800000	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	693000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1246000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	1487000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	1395000	USD
CY2013Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	763000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	84000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	31000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	65000	USD
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	252000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	60000	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
CY2014Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	688000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1257000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-147000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-611000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16711000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3600000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3400000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58840000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48122000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11199000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13735000	USD
CY2014Q4	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	600000	USD
CY2013Q4	us-gaap	Marketable Securities MarketableSecurities	3005000	USD
CY2014Q4	us-gaap	Marketable Securities MarketableSecurities	0	USD
CY2013Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	795000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13272000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4647000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11892000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22998000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	321000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-30857000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-41303000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-19071000	USD
CY2013Q4	us-gaap	Noncurrent Assets NoncurrentAssets	18312000	USD
CY2014Q4	us-gaap	Noncurrent Assets NoncurrentAssets	10475000	USD
CY2014	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	operating_segment
CY2012	us-gaap	Operating Expenses OperatingExpenses	118811000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	73068000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	54418000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-30513000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-41146000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-19111000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	14037000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2743000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	1400000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2818000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2736000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2677000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2827000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	236000	USD
CY2013	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	0	USD
CY2014	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	400000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	306000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	294000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	271000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	104000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-110000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	70000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	68000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2012	us-gaap	Other Expenses OtherExpenses	326000	USD
CY2013	us-gaap	Other Expenses OtherExpenses	304000	USD
CY2014	us-gaap	Other Expenses OtherExpenses	234000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5044000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4263000	USD
CY2012	us-gaap	Payments For Restructuring PaymentsForRestructuring	1123000	USD
CY2013	us-gaap	Payments For Restructuring PaymentsForRestructuring	877000	USD
CY2014	us-gaap	Payments For Restructuring PaymentsForRestructuring	238000	USD
CY2012	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2013	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	465000	USD
CY2014	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	815000	USD
CY2012	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20638000	USD
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2933000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1175000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	302000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1567000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1255000	USD
CY2014Q1	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	1500000	USD
CY2012	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	0	USD
CY2013	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	0	USD
CY2014	us-gaap	Proceeds From Divestiture Of Interest In Consolidated Subsidiaries ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries	1500000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9000	USD
CY2012	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	68000	USD
CY2013	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2014	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	800000	USD
CY2012	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	238000	USD
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	167000	USD
CY2012	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	0	USD
CY2013	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	0	USD
CY2014	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	282000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1257000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	318000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	195000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	37907000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	37288000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8446000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3995000	USD
CY2013	us-gaap	Property Plant And Equipment Transfers And Changes PropertyPlantAndEquipmentTransfersAndChanges	0	USD
CY2014	us-gaap	Property Plant And Equipment Transfers And Changes PropertyPlantAndEquipmentTransfersAndChanges	1841000	USD
CY2012	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	133000	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	386000	USD
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	11000	USD
CY2012	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	49977000	USD
CY2013	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	6868000	USD
CY2014	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	14945000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56785000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31606000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22755000	USD
CY2013Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	711000	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	711000	USD
CY2012	us-gaap	Restructuring Charges RestructuringCharges	3109000	USD
CY2013	us-gaap	Restructuring Charges RestructuringCharges	809000	USD
CY2012Q4	us-gaap	Restructuring Reserve RestructuringReserve	420000	USD
CY2013Q4	us-gaap	Restructuring Reserve RestructuringReserve	277000	USD
CY2014Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2012	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	153000	USD
CY2013	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	26000	USD
CY2014	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	39000	USD
CY2012	us-gaap	Restructuring Reserve Settled Without Cash1 RestructuringReserveSettledWithoutCash1	1413000	USD
CY2013	us-gaap	Restructuring Reserve Settled Without Cash1 RestructuringReserveSettledWithoutCash1	49000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-256859000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275930000	USD
CY2012	us-gaap	Revenue From Grants RevenueFromGrants	2247000	USD
CY2013	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2014	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2012	us-gaap	Revenues Revenues	88298000	USD
CY2013	us-gaap	Revenues Revenues	31922000	USD
CY2014	us-gaap	Revenues Revenues	35307000	USD
CY2012	us-gaap	Royalty Revenue RoyaltyRevenue	150000	USD
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	4631000	USD
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	7298000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7838000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	29000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	87000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	814000	USD
CY2012	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	35924000	USD
CY2013	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	20423000	USD
CY2014	us-gaap	Sales Revenue Goods Gross SalesRevenueGoodsGross	13064000	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31379000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26908000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21937000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	5076000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	4389000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	4620000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	6560731	shares
CY2014	us-gaap	Stock Issued During Period Shares Issued For Cash StockIssuedDuringPeriodSharesIssuedForCash	3308	shares
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1257000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	318000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	195000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	102690000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	78440000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	41483000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	26311000	USD
CY2014Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	100000	USD
CY2012	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	-647000	USD
CY2013	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	104000	USD
CY2014	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	-110000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6611000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7429000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8306000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	280000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	232000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	11000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	29000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	-47000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	718000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1116000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	346000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	316000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	6000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	187000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	158000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1000000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	500000	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8600000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14600000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5200000	USD
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36768000	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38231000	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38209000	shares
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments that are potentially subject to concentration of credit risk primarily consist of: cash equivalents, short-term investments, accounts receivable, marketable securities, and restricted cash. We invest cash that is not required for immediate operating needs principally in money market funds and corporate securities through banks and other financial institutions in the United States, as well as in foreign countries.</font></div></div>
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these notes to the consolidated financial statements, the “Company,” "we," "us,'" and "our" refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We develop biocatalysts for the pharmaceutical and fine chemicals markets. Our proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biocatalysts are enzymes or microbes that initiate and/or accelerate chemical reactions. Manufacturers have historically used naturally occurring biocatalysts to produce many goods used in everyday life. However, inherent limitations in naturally occurring biocatalysts have restricted their commercial use. Our proprietary CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">protein engineering </font><font style="font-family:inherit;font-size:10pt;">technology platform, which introduces genetic mutations into microorganisms in order to give rise to changes in enzymes that they produce, is able to overcome many of these limitations, allowing us to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. Once potentially beneficial mutations are identified through this proprietary process, combinations of these mutations can then be tested until variant enzymes have been created that exhibit marketable performance characteristics superior to competitive products. This process allows for continuous, efficient improvements to the performance of enzymes. In the past, we implemented our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">protein engineering </font><font style="font-family:inherit;font-size:10pt;">technology platform through paid collaborations with our customers. In July 2014, we entered into our first license agreement pursuant to which we granted a license to a global pharmaceutical company to use our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">protein engineering </font><font style="font-family:inherit;font-size:10pt;">technology platform for their internal development purposes, and we are pursuing additional license opportunities with other customers.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have commercialized our technology and products in the pharmaceuticals market, which is our primary business focus. Our pharmaceutical customers, which include several of the largest global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development, including in the production of some of the world's best-selling and fastest growing drugs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also use our technology to develop biocatalysts for use in the fine chemicals market. The fine chemicals market is similar to our pharmaceutical business and consists of several large market verticals, including: food, animal feed, flavors, fragrances, and agricultural chemicals.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also used our technology to develop an early stage, novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria ("PKU") in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient.</font></div></div>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. We regularly assess these estimates which primarily affect revenue recognition, accounts receivable, inventories, the valuation of investment securities and marketable securities, assets held for sale, intangible assets, goodwill arising out of business acquisitions, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001200375-15-000008-index-headers.html	Edgar Link	pending
0001200375-15-000008-index.html	Edgar Link	pending
0001200375-15-000008.txt	Edgar Link	pending
0001200375-15-000008-xbrl.zip	Edgar Link	pending
cdxs-20141231.xml	Edgar Link	completed
cdxs-20141231.xsd	Edgar Link	pending
cdxs-20141231x10k.htm	Edgar Link	pending
cdxs-20141231_cal.xml	Edgar Link	unprocessable
cdxs-20141231_def.xml	Edgar Link	unprocessable
cdxs-20141231_lab.xml	Edgar Link	unprocessable
cdxs-20141231_pre.xml	Edgar Link	unprocessable
exhibit211cdxs-20141231.htm	Edgar Link	pending
exhibit231cdxs-20141231.htm	Edgar Link	pending
exhibit232cdxs-20141231.htm	Edgar Link	pending
exhibit311cdxs-20141231.htm	Edgar Link	pending
exhibit312cdxs-20141231.htm	Edgar Link	pending
exhibit321cdxs-20141231.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
preformancestockgraph.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXS
CODEXIS, INC. Stock $cdxs

2015 Q1 Form 10-K Financial Statement

#000120037515000008 Filed on March 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS CODEXIS, INC. Stock $cdxs

2015 Q1 Form 10-K Financial Statement

#000120037515000008 Filed on March 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS
CODEXIS, INC. Stock $cdxs